There are 2789 resources available
703P - Camrelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
Presenter: Nianzeng Xing
Session: ePoster Display
704P - Treatment patterns among patients with advanced urothelial carcinoma (aUC) in the USA
Presenter: Alicia Morgans
Session: ePoster Display
705P - Systematic literature review (SLR) and network meta-analysis (NMA) of first-line (1L) therapies for locally advanced/metastatic urothelial carcinoma (la/mUC)
Presenter: Lisa Bloudek
Session: ePoster Display
706P - Real-world study assessing physician rationale for initiating first-line (1L) immuno-oncology (IO) therapy for patients with advanced urothelial cancer (aUC)
Presenter: Mayank Ajmera
Session: ePoster Display
707P - Treatment pattern and overall survival among patients with locally advanced or metastatic urothelial carcinoma: Results from a complete nationwide unselected real-world registry study in Denmark from 2010 to 2017
Presenter: Jorgen Bjerggaard Jensen
Session: ePoster Display
710P - Comprehensive genomic profiling (CGP) of small cell neuroendocrine carcinoma of the bladder (NEBC)
Presenter: Andrea Necchi
Session: ePoster Display
711P - Outcomes according to genomic characteristics of patients with metastatic urothelial carcinoma in phase I/II trials
Presenter: Cedric Pobel
Session: ePoster Display
712P - Analysis of fibroblast growth factor receptor 3 aberrations in bladder cancer, for enabling personalized and effective therapy based on FGFR inhibitor
Presenter: Roman Sosnowski
Session: ePoster Display